Relapsed or refractory HIV associated lymphoma
Conditions
Interventions
Salvage regimen
etoposide60mg/m2 div for 2hrs day1-4 mPSL500mg div for 30min day1-5 carboplatin100mg/m2 cont.div day1-4 AraC2g/m2 div for 3hrs day5 Rituximab375mg div day1 for a case with CD20 positive 1course=2
MCNU300mg/m2 div for 1hr day-6 etoposide200mg/m2 div for 3hrs day-5~-3 AraC200mg/m2 div for 3 hrs day-5~-3 L-PAM140mg/m2 bolus iv day-2
Sponsors
International Medical Center of JAPAN
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria for salvage regimen; 1)HIV positive 2)refractory to first line chemotherapy or relapsed non-Hodgkin's lymphoma 3)ECOG PS0-4 4)Well controlled HIV rirul load with HAART 5)Written informed consent sheet must be obtained before entry to the trial Inclusion criteria for autologous peripheral blood stem cell transplantation; 1)More than 2x10E6/kg of CD34-positive cells were collected 2)Patients who achieved PR or CR after the salvage regimen 3)Age:15=< <60 4)ECOG PS0-2 5)HIV virus load should be well controlled with HAART 6)No active opportunistic infection 7)Written informed consent sheet must be obtained
Exclusion criteria
Exclusion criteria: Exclusion criteria for salvage regimen 1)Organ dysfunction a)EF<40% by cardiac sonography b)PaO2<50mmHg or SaO2<90% c)serumCr>3.0mg/dl d)Total-bilirubin>3.0mg/dl or ALT>five times upper limit of the institutional normal value 2)Serious active infection Exclusion criteria for PBSCT 1)Organ dysfunction a)EF<50% by cardiac sonography b)PaO2<60mmHg c)serumCr>2.0mg/dl d)Total-bilirubin>2.0mg/dl or ALT>twice of upper limit of the institutional normal value 2)Uncontrollable HIV virus load and resistant to HAART 3)Uncontrollable diabetes which is resistant to insulin 4)Uncontrollable hypertension 5)Intractable and active infection 6)Intractable invasion of lymphoma to CNS 7)Pregnant or possible pregnant women or breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2year over all survival | — |
Secondary
| Measure | Time frame |
|---|---|
| survival at 100 days after transplantation, CR rate, therapy related toxicity, the number of collected stem cells, the rate of engraftment, the number of CD4 positive cells, the quantity of HIV-virus | — |
Countries
Japan
Contacts
Public ContactShotaro Hagiwara
International Medical Center of JAPAN Division of Hematology
Outcome results
None listed